Pilot trial of etanercept in the treatment of inclusion-body myositis

Inclusion-body myositis (IBM) is an inflammatory muscle disease that has proven resistant to treatment. Tumor necrosis factor molecules have been detected in muscle biopsies from patients with IBM. Etanercept is a TNFalpha receptor fusion protein that binds and inactivates tumor necrosis factor. Nin...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neurology 2006-01, Vol.66 (2 Suppl 1), p.S123-S124
Hauptverfasser:	Barohn, R J, Herbelin, L, Kissel, J T, King, W, McVey, A L, Saperstein, D S, Mendell, J R
Format:	Artikel
Sprache:	eng
Schlagworte:	Cohort Studies Disease Progression Etanercept Hand Strength Humans Immunoglobulin G - therapeutic use Isometric Contraction - drug effects Myositis, Inclusion Body - drug therapy Pilot Projects Receptors, Tumor Necrosis Factor - therapeutic use Treatment Failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!